Navigation Links
3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
Date:12/4/2013

MENLO PARK, Calif., Dec. 4, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the recent initiation of a Phase 1 clinical study of TVB-2640 in patients with advanced solid tumors.  TVB-2640 is an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors.  FASN is an enzyme responsible for the synthesis of palmitic acid and has a key role in tumor metabolism, lipid signaling and tumor cell survival.

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"For tumors to grow, cancer cells need to process more fuel than normal cells.  The ability to interfere in tumor cell metabolism is an extremely compelling avenue for oncology drug development," said Jeffrey Infante, M.D., Sarah Cannon Research Institute in Nashville, TN and lead investigator for the 3-V clinical trial.  "TVB-2640 is the first inhibitor of FASN to enter the clinic. Our center is excited to be leading the Phase 1 clinical study for this emerging and promising anti-cancer therapy."

The Phase 1 open-label, dose-escalation trial will enroll patients with advanced solid tumors whose cancer has become refractory to standard therapy, and for whom no useful treatment exists.  Patients will receive TVB-2640 once daily for 21 days.  The primary endpoint for the Phase 1 study is the identification of any dose-limiting toxicities and the establishment of a maximum-tolerated dose (MTD) for oral TVB-2640.  Secondary and exploratory endpoints include safety, pharmacokinetics, and initial signs of efficacy and evidence of FASN biomarker activity.

"With the initiation of this Phase 1 clinical trial, we look forward to testing our hypothesis that blocking FASN could provide a significant benefit in patients with solid tumors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  Data from this trial will provide further information on the safety profile, dosing and selection of cancer types in anticipation of future studies for TVB-2640."

FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers. FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner and single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts. In addition, 3-V has demonstrated potential synergy of its FASN inhibitors with cytotoxic agents.  

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The
3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact Information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
2. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
3. ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
4. 3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
5. Lilly Statement on Contribution to Indiana Biosciences Research Institute
6. Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
7. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
10. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... Valentine’s Day is nearly upon us, and most singles could probably use ... hair, and a sparkling personality are all well and good, but if somebody smells ... with Rover. (Actually, man’s best friend might not even want to be near those ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... In the early or “honeymoon” stage of a relationship, couples strive to put ... to be romantic, and may exaggerate a strength or two in an effort to ... , A recent study from Queendom.com , however, suggests that new couples who ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of ... Evangeline Parishes. The purpose of these scholarships is to encourage applicants to pursue ... to seek employment within these two parishes. , “We have available jobs in ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, ... ... in Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, ... burner issue in the life cycle of pharmaceutical products, garnering increased attention from ...
Breaking Medicine News(10 mins):